NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT06704724 2026-03-13A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.PfizerPhase 1 Active not recruiting30 enrolled
NCT04449874 2026-02-12A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationGenentech, Inc.Phase 1 Active not recruiting498 enrolled
NCT02438722 2026-02-06S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung CancerSWOG Cancer Research NetworkPhase 2/3 Active not recruiting174 enrolled 18 charts
NCT01025089 2026-01-07Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic CarcinomaMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting18 enrolled
NCT06764771 2025-12-17A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsBristol-Myers SquibbPhase 1 Active not recruiting437 enrolled
NCT04585035 2025-03-18Study to Evaluate D-1553 in Subjects With Solid TumorsInventisBio Co., LtdPhase 1/2 Active not recruiting180 enrolled